Canada - English - Health Canada

glaxosmithkline inc - diphtheria toxoid adsorbed; tetanus toxoid adsorbed; pertussis toxoid adsorbed; filamentous haemagglutinin adsorbed; pertactin adsorbed; inactivated poliovirus type i; inactivated poliovirus type ii; inactivated poliovirus type iii - suspension - 2.5lf; 5.0lf; 8mcg; 8mcg; 2.5mcg; 40d; 8d; 32d - diphtheria toxoid adsorbed 2.5lf; tetanus toxoid adsorbed 5.0lf; pertussis toxoid adsorbed 8mcg; filamentous haemagglutinin adsorbed 8mcg; pertactin adsorbed 2.5mcg; inactivated poliovirus type i 40d; inactivated poliovirus type ii 8d; inactivated poliovirus type iii 32d - vaccines

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - pertussis filamentous haemagglutinin, quantity: 10 microgram/ml; pertussis fimbriae 2 + 3, quantity: 10 microgram/ml; tetanus toxoid, quantity: 80 iu/ml; pertussis toxoid, quantity: 20 microgram/ml; diphtheria toxoid, quantity: 60 iu/ml; pertactin, quantity: 6 microgram/ml - injection, suspension - excipient ingredients: aluminium phosphate; water for injections; phenoxyethanol - tripacel is indciated for primary immunisation against diphtheria, tetanus and pertussis when commenced between 2 months and 12 months of age. tripacel is also indicated for the fourth and fifth dose for children from 15 months of age up to their eighth birthday who have been immunised previously with three or four doses of diphtheria, tetanus and pertussis (whole cell or acellular) vaccines.

Ireland - English - HPRA (Health Products Regulatory Authority)

glaxosmithkline (ireland) limited - pertussis toxoid filamentous haemagglutinin (fha) pertactin diphtheria toxoid tetanus toxoid haemophilus influenzae type b polysaccharide tetanus toxoid - powder for suspension for injection

Canada - English - Health Canada

aventis pasteur limited - diphtheria toxoid; tetanus toxoid; pertussis vaccine - liquid - 25lf; 5lf; 12unit - diphtheria toxoid 25lf; tetanus toxoid 5lf; pertussis vaccine 12unit - toxoids

Canada - English - Health Canada

aventis pasteur limited - diphtheria toxoid - liquid - 0.2lf - diphtheria toxoid 0.2lf - diphtheria

Canada - English - Health Canada

glaxosmithkline inc - pertussis toxoid; filamentous haemagglutinin; pertactin; diphtheria toxoid; tetanus toxoid; inactivated poliovirus type i; inactivated poliovirus type ii; inactivated poliovirus type iii - suspension - 25mcg; 25mcg; 8mcg; 30unit; 40unit; 40unit; 8unit; 32unit - pertussis toxoid 25mcg; filamentous haemagglutinin 25mcg; pertactin 8mcg; diphtheria toxoid 30unit; tetanus toxoid 40unit; inactivated poliovirus type i 40unit; inactivated poliovirus type ii 8unit; inactivated poliovirus type iii 32unit - vaccines

Australia - English - Department of Health (Therapeutic Goods Administration)

maxx pharma pty ltd - tetanus toxoid, quantity: 40 iu; diphtheria toxoid, quantity: 20 iu; poliovirus, quantity: 80 dagu; pertussis fimbriae 2 + 3, quantity: 5 microgram; haemophilus influenza type b polyribose ribitol phosphate, quantity: 3 microgram; pertussis toxoid, quantity: 20 microgram; pertussis filamentous haemagglutinin, quantity: 20 microgram; hepatitis b surface antigen, quantity: 10 microgram; pertactin, quantity: 3 microgram - injection, suspension - excipient ingredients: aluminium; water for injections; dibasic sodium phosphate; monobasic sodium phosphate - vaxelis (dtpa5-hb-ipv-hib) is indicated for primary and booster vaccination in infants and toddlers from the age of 6 weeks, against diphtheria, tetanus, pertussis, hepatitis b, poliomyelitis and invasive diseases caused by haemophilus influenzae type b (hib).,the use of vaxelis should be in accordance with official recommendations.

Australia - English - Department of Health (Therapeutic Goods Administration)

maxx pharma pty ltd - tetanus toxoid, quantity: 40 iu; diphtheria toxoid, quantity: 20 iu; poliovirus, quantity: 80 dagu; pertussis fimbriae 2 + 3, quantity: 5 microgram; haemophilus influenza type b polyribose ribitol phosphate, quantity: 3 microgram; pertussis toxoid, quantity: 20 microgram; pertussis filamentous haemagglutinin, quantity: 20 microgram; hepatitis b surface antigen, quantity: 10 microgram; pertactin, quantity: 3 microgram - injection, suspension - excipient ingredients: aluminium; water for injections; dibasic sodium phosphate; monobasic sodium phosphate - vaxelis (dtpa5-hb-ipv-hib) is indicated for primary and booster vaccination in infants and toddlers from the age of 6 weeks, against diphtheria, tetanus, pertussis, hepatitis b, poliomyelitis and invasive diseases caused by haemophilus influenzae type b (hib).,the use of vaxelis should be in accordance with official recommendations.

Canada - English - Health Canada

glaxosmithkline inc - haemophilus influenzae type b-prp; filamentous haemagglutinin; pertactin; hepatitis b surface antigen (recombinant); diphtheria toxoid; tetanus toxoid; poliovirus type 1 mahoney (inactivated); poliovirus type 2 mef1 (inactivated); poliovirus type 3 saukett (inactivated); pertussis toxoid; tetanus toxoid adsorbed - suspension - 10mcg; 25mcg; 8mcg; 10mcg; 25lf; 10lf; 40unit; 8unit; 32unit; 25mcg; 40mcg - haemophilus influenzae type b-prp 10mcg; filamentous haemagglutinin 25mcg; pertactin 8mcg; hepatitis b surface antigen (recombinant) 10mcg; diphtheria toxoid 25lf; tetanus toxoid 10lf; poliovirus type 1 mahoney (inactivated) 40unit; poliovirus type 2 mef1 (inactivated) 8unit; poliovirus type 3 saukett (inactivated) 32unit; pertussis toxoid 25mcg; tetanus toxoid adsorbed 40mcg - vaccines

Australia - English - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - diphtheria toxoid, quantity: 4 iu/ml; tetanus toxoid, quantity: 40 iu/ml - injection, suspension - excipient ingredients: water for injections; sodium hydroxide; aluminium hydroxide hydrate; sodium chloride - vaccination of children (greater than or equal to 5 years of age) and adults who have previously received at least 3 doses of a vaccine for primary immunisation against diphtheria and tetanus. adt booster is not intended for primary immunisation against diphtheria and tetanus. use of adt booster should be scheduled in accordance with official national recommendations.